MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common shares, net of...
$398,090K
Proceeds from exercise of
options and espp...
$27,936K
Net cash provided by
financing activities
$426,026K
Effect of exchange rate
changes on cash
$95K
Increase (decrease) in
cash
$49,302K
Canceled cashflow
$376,819K
Acquired in-process
research and development
$96,253K
Stock-based compensation
expense
$72,499K
Accounts payable and
accrued expenses
$44,894K
Accounts receivable
-$25,000K
Depreciation and
amortization
$19,479K
Other liabilities,
net
$4,258K
Prepaid expenses and
other assets
-$3,337K
Maturities of marketable
debt securities
$1,011,277K
Sale of equity
securities
$702K
Net cash used in
operating activities
-$345,014K
Net cash used in
(provided by) investing...
-$31,805K
Canceled cashflow
$265,720K
Canceled cashflow
$1,011,979K
Net loss
-$581,599K
Purchases of marketable
debt securities
$1,008,170K
Other non-cash items,
net
$23,528K
Operating lease assets and
liabilities
-$5,210K
Deferred revenue
-$397K
Purchase of in-process
research and development
$25,000K
Investment in equity
securities
$9,700K
Purchase of property,
plant and equipment
$914K
Back
Back
Cash Flow
source: myfinsight.com
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP)